Lichen Planus: A Cross-Sectional Evaluation of US Dermatologists' Comorbidity Screening and Management Patterns.

IF 3.5 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-24 DOI:10.1007/s13555-025-01422-1

Savanna I Vidal, Nikita Menta, Adam Friedman

{"title":"Lichen Planus: A Cross-Sectional Evaluation of US Dermatologists' Comorbidity Screening and Management Patterns.","authors":"Savanna I Vidal, Nikita Menta, Adam Friedman","doi":"10.1007/s13555-025-01422-1","DOIUrl":null,"url":null,"abstract":"Introduction: Lichen planus (LP) is a chronic inflammatory dermatosis affecting up to 0.91% of the US's population. LP is associated with various comorbid conditions, among them autoimmune conditions. LP has various treatment strategies, although none are US Food and Drug Administration (FDA)-approved; this is further complicated by the lack of any clinical or expert guidelines. This study aimed to explore dermatology practitioners' comorbidity screening patterns and treatment practices for management of LP.Methods: An institutional review board (IRB)-approved, anonymous survey was distributed to members of the ODAC Conference listserv, targeting dermatology practitioners. The survey collected data on demographics, comorbidity screening, and treatment strategies.Results: A total of 406 respondents (17.4% response rate) participated. Hepatitis C virus was the most screened for condition (91.0%), despite its overall low prevalence in patients with LP. Screening rates for highly prevalent comorbidities such as hypertension (10.1%), dyslipidemia (9.7%), depression (18.7%), and anxiety (17.3%) were low. Importantly, almost one-third (32.5%) of respondents reported performing no screening for any comorbid conditions. Topical corticosteroids were the most prescribed therapy (97.8%), followed by topical calcineurin inhibitors (67.7%) and intralesional corticosteroids (64.8%), consistent with high-level evidence for their use in LP treatment. Phototherapy and systemic treatments, including oral immunosuppressants and retinoids, were less frequently utilized despite strong evidence supporting their use.Conclusion: These data highlight gaps in the comorbidity screening practices among dermatology practitioners managing LP, with significant underscreening for prevalent conditions. While respondents commonly relied on some evidence-based topical treatments, there is notable underutilization of systemic treatments for moderate to severe disease. These results emphasize the need for clinical guidelines for LP management, aiming to enhance patient care and outcomes.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1455-1465"},"PeriodicalIF":3.5000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092853/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01422-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Lichen planus (LP) is a chronic inflammatory dermatosis affecting up to 0.91% of the US's population. LP is associated with various comorbid conditions, among them autoimmune conditions. LP has various treatment strategies, although none are US Food and Drug Administration (FDA)-approved; this is further complicated by the lack of any clinical or expert guidelines. This study aimed to explore dermatology practitioners' comorbidity screening patterns and treatment practices for management of LP.

Methods: An institutional review board (IRB)-approved, anonymous survey was distributed to members of the ODAC Conference listserv, targeting dermatology practitioners. The survey collected data on demographics, comorbidity screening, and treatment strategies.

Results: A total of 406 respondents (17.4% response rate) participated. Hepatitis C virus was the most screened for condition (91.0%), despite its overall low prevalence in patients with LP. Screening rates for highly prevalent comorbidities such as hypertension (10.1%), dyslipidemia (9.7%), depression (18.7%), and anxiety (17.3%) were low. Importantly, almost one-third (32.5%) of respondents reported performing no screening for any comorbid conditions. Topical corticosteroids were the most prescribed therapy (97.8%), followed by topical calcineurin inhibitors (67.7%) and intralesional corticosteroids (64.8%), consistent with high-level evidence for their use in LP treatment. Phototherapy and systemic treatments, including oral immunosuppressants and retinoids, were less frequently utilized despite strong evidence supporting their use.

Conclusion: These data highlight gaps in the comorbidity screening practices among dermatology practitioners managing LP, with significant underscreening for prevalent conditions. While respondents commonly relied on some evidence-based topical treatments, there is notable underutilization of systemic treatments for moderate to severe disease. These results emphasize the need for clinical guidelines for LP management, aiming to enhance patient care and outcomes.

查看原文本刊更多论文

扁平苔藓：美国皮肤科医生的合并症筛查和管理模式的横断面评估。

简介：扁平苔藓（LP）是一种慢性炎症性皮肤病，影响美国人口的0.91%。LP与多种合并症有关，其中包括自身免疫性疾病。LP有多种治疗策略，尽管没有一种是美国食品和药物管理局（FDA）批准的；由于缺乏任何临床或专家指南，情况进一步复杂化。本研究旨在探讨皮肤科医师对LP的合并症筛查模式及治疗方法。方法：一份机构审查委员会（IRB）批准的匿名调查被分发给ODAC会议列表的成员，目标是皮肤科从业人员。该调查收集了人口统计、合并症筛查和治疗策略方面的数据。结果：共有406人参与调查，回复率为17.4%。丙型肝炎病毒是筛查最多的疾病（91.0%），尽管其在LP患者中的总体患病率较低。高血压（10.1%）、血脂异常（9.7%）、抑郁（18.7%）和焦虑（17.3%）等高发合并症的筛查率较低。重要的是，近三分之一（32.5%）的受访者报告没有对任何合并症进行筛查。外用皮质类固醇是最常用的治疗方法（97.8%），其次是外用钙调磷酸酶抑制剂（67.7%）和局灶内皮质类固醇（64.8%），这与它们在LP治疗中使用的高水平证据一致。光疗和全身治疗，包括口服免疫抑制剂和类维生素a，尽管有强有力的证据支持其使用，但使用频率较低。结论：这些数据突出了皮肤科医生管理LP的合并症筛查实践的差距，对流行疾病的筛查明显不足。虽然应答者通常依赖于一些基于证据的局部治疗，但对中度至重度疾病的全身治疗的利用明显不足。这些结果强调了LP管理临床指南的必要性，旨在提高患者的护理和结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.